Nicolaus Kröger, ASH 2018 – Treatment of Myelodysplastic Syndrome in Elderly Patients
Professor Nicolaus Kröger spoke to us at ASH 2018 about the major unmet needs in the treatment of myelodysplastic syndrome in elderly patients, and his phase III study comparing 5-azacytidine induction followed by allogeneic stem cell transplantation versus continuous 5-azacytidine according to donor availability in elderly patients with myelodysplastic syndrome.
Questions:
1. What are the major unmet needs in the treatment of myelodysplastic syndrome (MDS) in elderly patients? (0:10)
2. What is the rationale for induction therapy with 5-azacytidine prior to allogeneic hematopoietic stem cell transplantation (HSCT)? (0:58)
3. Could you tell us a little about the rationale for and design of the phase III study you are presenting at ASH? (2:08)
4. What were the findings of this study? (3:24)
5. What are the implications of these findings for the future treatment of elderly patients with MDS? (4:34)
Speaker disclosures: Nicolaus Kröger has nothing to declare in relation to this interview.
Filmed at the 60th American Society of Hematology (ASH) 2018 Annual Meeting, San Diego, CA, US, December 1–4, 2018.
